SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies the side effects and how well giving monoclonal
antibody SGN-30 together with combination chemotherapy works in treating patients with
Hodgkin lymphoma that has returned after a period of improvement or did not respond to
previous treatment. Monoclonal antibodies, such as SGN-30, may interfere with the ability of
cancer cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine
hydrochloride, vinorelbine tartrate, and pegylated liposomal doxorubicin hydrochloride, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving monoclonal antibody SGN-30 together with combination
chemotherapy may kill more cancer cells and shrink tumors.